AIM Completes Series A to Accelerate Growth of its Organ-on-a-Chip Business

November 19, 2020 -- Boston, MA & Singapore -- AIM Biotech completed its series A financing to accelerate growth of its organ-on-a-chip business. The company's advanced research tool mimics human organs and disease models in the lab to improve, accelerate and reduce the cost of drug discovery for academic, translational and clinical researchers. The round was led by Wavemaker Partners and included participation from SEEDS Capital (the investment arm of Enterprise Singapore), Elevate, Wavemaker Three-Sixty Health, Black Kite Investment and others.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Raises Series A financing to accelerate growth of its organ-on-a-chip business.
• Led by Wavemaker Partners and included participation from Enterprise Singapore, Elevate, Wavemaker Three-Sixty Health, Black Kite Investment and others.
• Use proceeds to establish a US subsidiary, expand commercial operations, grow world-class biopharma contract research service located in Singapore and develop new disease-specific chips for global biotech and pharmaceutical companies.

Click image above to view full announcement.

About AIM Biotech

AIM Biotech's platform and world-class lab services let drug researchers get more relevant, human-focused data at every stage of development. That means more informed decisions and less wasted time. Streamline your workflow. Rethink how you look at life sciences. It's time to add the human element.

About Wavemaker Partners

Wavemaker Partners is Southeast Asia's go-to early-stage VC for enterprise and deep tech. 116 out of the 136 (85%) portfolio companies we have invested in since 2012 are in enterprise & deep tech. Our portfolio includes startups in software, AI and cybersecurity as well as precision agriculture, cleantech, additive manufacturing and laser communications. Recent exits include TradeGecko's acquisition by Intuit, Moka's and Coins.ph's acquisitions by Gojek, Red Dot Payment by PayU/Naspers and Wavecell by 8×8.

For more information, please visit wavemaker.vc

Contacts:

Media & Investors

[email protected]

Source: AIM Biotech

Distributed by: Reportable, Inc.